

Alzheimer’s disease affects six million Americans, stealing memories years before it takes lives. Aduhelm, the first drug intended to treat the Alzheimer’s disease process rather than symptoms, was highly anticipated by patients and families. But it has disappointed on many levels. It isn’t clear that it actually helps patients and troubling side effects are common. But what I find worst is the enormous, unjustified price Biogen is charging for it and the sacrifices necessary to afford it.
Aduhelm hasn’t delivered on its promises. The FDA’s independent expert advisory committee found that, while there is evidence from clinical trials that the drug reduced plaques in the brains of Alzheimer’s patients, there are doubts whether the drug slowed cognitive decline. Also, over 40% of Alzheimer’s patients who received the drug in clinical trials experienced brain swelling, headaches, dizziness, and small bleeds in the brain. The committee voted overwhelmingly not to approve the drug. When the FDA approved the drug anyway, three members of the committee resigned.
Setting aside the issue of its questionable efficacy, Biogen has set the price for Aduhelm at $56,000 per year. In addition, the drug must be administered intravenously every month, costing tens of thousands of dollars more for patients and the health system. As most Alzheimer’s patients are over age 65, the brunt of the costs will fall on Medicare’s Part B program. At that price, the cost of the drug for Connecticut’s 80,000 residents with Alzheimer’s would total $4.5 billion this year – and would rise to $5.1 billion by 2025. For context, in 2014 all Connecticut residents’ total prescription drug spending was $5.3 billion. The cost of Aduhelm for one Connecticut patient would fund the cost of assisted living or 43 more hours per week of home health care for that patient.
The price has attracted widespread criticism. Based on the evidence, ICER, the national leader in value-based pricing, determined that a fair annual price for the drug would be between $2,500 and $8,300. The Alzheimer’s Association called Biogen’s price for the drug “simply unacceptable. For many, this price will pose an insurmountable barrier to access, it complicates and jeopardizes sustainable access to this treatment, and may further deepen issues of health equity. We call on Biogen to change this price.”
Aduhelm’s costs will fall on both Alzheimer’s patients and the entire health system. Aduhelm will cost Medicare beneficiaries with Alzheimer’s $11,500 each year in coinsurance; that is 39% of the average beneficiary’s annual income. Aduhelm’s costs will increase Medicare premiums for all beneficiaries and those with Medigap insurance that covers coinsurance will see their premiums skyrocket. Aduhelm’s extreme price may jeopardize funding for more promising Alzheimer’s drugs that are now in the pipeline.
Support authentic, locally owned and operated public service journalism!
The only upside of the controversy and the massive financial burden Aduhelm will place on patients and the health system is that it may finally prompt meaningful prescription drug price reform and pharmaceutical company accountability.

Ellen Andrews, PhD, is the executive director of the CT Health Policy Project. Follow her on Twitter @CTHealthNotes.
The views, opinions, positions, or strategies expressed by the author are theirs alone, and do not necessarily reflect the views, opinions, or positions of CTNewsJunkie.com.
More from Ellen Andrews

OP-ED | Policymakers Did Little to Lower Healthcare Costs This Session
Last year, Connecticut policymakers accomplished little to reduce the cost of healthcare, and those costs haven’t gotten any better since then. Incumbents will be asked what they did this year to provide some relief. Unfortunately, they have little to offer.
Keep reading
ANALYSIS | Fact Check Shows That Raising Primary Care Spending Doesn’t Lower Total Healthcare Costs
Ellen Andrews checks the facts on HB 5042 and says it’s very appealing to think that increasing investments in prevention and care management will reduce total healthcare costs. It avoids the difficult work of getting large health systems and drug companies to lower their extreme prices. But unfortunately, she says there is no evidence to…
Keep reading
OP-ED | Children Deserve Healthcare, Regardless of Immigration Status
Last year, Connecticut policymakers made the smart and moral decision to provide HUSKY coverage to children from low-income families through age eight, regardless of immigration status, starting next year … but it makes more sense to cover all children.
Keep reading
Connecticut Officials Tackle Drug Pricing
The cost of prescription drugs is increasing, and Gov. Ned Lamont and some lawmakers are renewing their push to lower the cost by telling companies how much they can charge. “A survey in 2018 found that 20 percent of people of Connecticut residents were either cutting pills or skipping prescriptions because they couldn’t afford it,”…
Keep reading
OP-ED | Class Action Against Hartford Healthcare Changes the Landscape
Ellen Andrews says the new lawsuit filed last week by six brave Connecticut residents alleges that Hartford Healthcare is manipulating the market to drive out competition and raise prices.
Keep reading
OP-ED | The Governor’s Plan To Lower Healthcare Costs – What’s In It, And What’s Missing
Ellen Andrews highlights the good, the bad, and the ugly in Gov. Ned Lamont’s legislative package on healthcare.
Keep reading
OP-ED | How Much Do CT Hospitals Spend On Administration? No One Knows
Ellen Andrews tried to figure what the state knows about how hospitals spend their money. As they grow & charge more, do they improve patient care or just hire more administrators? We don’t know. But we should.
Keep reading
OP-ED | Connecticut’s Healthcare Market Regulation Is Broken
Healthcare consolidations are endangering access to care and driving up prices. But the state agency that is supposed to keep Connecticut’s healthcare market competitive isn’t acting.
Keep reading
OP-ED | The Brainard Fund Still Making A Difference After 64 Years
In 2010, I got a call that advocates only dream about.
Keep reading
OP-ED | It’s A Miracle – Under New Agreement, Medicare Will Negotiate Drug Prices
Democrats in Washington have negotiated a deal to allow Medicare to negotiate prices with drug companies. Americans pay 2.56 times higher drug prices than residents of other developed countries. Ellen Andrews says that politically, this is a seismic shift.
Keep readingMore Health Care News & Analysis
Med Board Fines Doc $10,000
The state Medical Examining Board on Tuesday fined an Oxford doctor $10,000 for fraudulently using another doctor’s name and Drug Enforcement Agency registration number to prescribe controlled substances to a family member. In addition to the fine, board also voted unanimously to reprimand the medical license of the doctor, Marc D. Legris, and ordered him…
Keep reading
Clinical Trials With Immunotherapy Drugs Are Source Of Hope And Challenges In Treating Aggressive Breast Cancer
Joshalyn Mills of Branford and Nancy Witz of Kensington had the best possible results after being treated in clinical trials with immunotherapy drugs for aggressive breast cancer: Their tumors were eliminated. But while there are dramatic successes with immunotherapy drugs, there are also many failures, and researchers are trying to find out why in hopes…
Keep reading
Coalition of Health Insurers Questions Viability of Connecticut Partnership Plan
Members of Connecticut’s Health Care Future, a coalition of health insurers, hospitals, and businesses, are questioning whether Connecticut lawmakers have done enough this year to protect teachers and municipal employees from increases in health insurance premiums. “Despite repeated bailouts from taxpayers, the Connecticut Partnership Plan continues to be a fiscal Titanic that demonstrates why government-controlled health…
Keep reading
AG’s Tackle Mental Health Parity
Attorneys General in Connecticut and Rhode Island threw their support Monday behind a coalition of mental health advocacy groups asking a federal appeals court to revisit a recent ruling giving insurance companies more flexibility to deny mental health claims.
Keep reading
Budget Green Lights Psychedelic Therapies
Buried in the budget Gov. Ned Lamont signed this week is a provision that would create a pilot program to allow Connecticut to be the first-in-the-nation to study the impact of psychedelic drugs like psilocybin and MDMA on patients with depression and PTSD. The budget now creates a pilot program within the Department of Mental…
Keep reading
Officials Highlight Effort To Boost Mental Health Services For Kids
At a Hartford-based community provider Wednesday, Gov. Ned Lamont and a handful of his agency commissioners highlighted the expected impact of more than $100 million in recently passed funding aimed at increasing behavioral health services for Connecticut children. The governor appeared at The Village for Families and Children, a recipient of new state funding included…
Keep reading